Effects of Gene Polymorphisms on Metabolic Features in Clozapine-treated Patients With Schizophrenia
NCT01324167 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 80
Last updated 2011-03-28
Summary
The investigators would like to know the association of gene polymorphisms and metabolic adversities in clozapine-treated patients with schizophrenia in Taiwan.
Conditions
- Schizophrenia
- Schizoaffective Disorder
Sponsors & Collaborators
-
Taipei Medical University WanFang Hospital
lead OTHER
Principal Investigators
-
Chun-Hsin Chen, MD · Taipei Medical University WanFang Hospital
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2010-05-31
- Completion
- 2011-04-30
Countries
- Taiwan
Study Locations
More Related Trials
-
The Study of Atypical Antipsychotics-induced Metabolic Disturbances
NCT00937755 ·Status: COMPLETED
-
Relationship Between Neurotransmitter Receptor Polymorphisms, Plasma Concentrations and Clinical Response to Clozapine
NCT00581932 ·Status: COMPLETED
-
The Mechanism of TCF7L2 and SLC30A8 on Antipsychotic-induced Metabolic Syndrome
NCT02093858 ·Status: UNKNOWN
-
Phenomics and Genomics of Clozapine Pharmacotherapy
NCT03253367 ·Status: UNKNOWN
-
Prevalence of the Metabolic Syndrome in SPR Taking Antipsychotics
NCT00569504 ·Status: UNKNOWN
-
A Psychopathological Study of Latent (Early) Schizophrenia: Clinical Pathology/Neuropsychological Dysfunctions
NCT00155519 ·Status: COMPLETED
-
The Prevalence of Obesity For Schizophrenia Inpatients in Taiwan
NCT01170689 ·Status: COMPLETED
-
A Positional Cloning Study on Schizophrenia
NCT00155649 ·Status: COMPLETED
-
Single Nucleotide Polymorphism (SNP) in Schizophrenia and Schizophrenia Spectrum Disorders: a Population Association Analysis With Hong Kong Chinese
NCT00562926 ·Status: COMPLETED
-
Psychopathology of Dissociative Disorders
NCT01388140 ·Status: UNKNOWN
-
Improving Outcome in Schizophrenia Through Identification of Genetic Risk Factors
NCT00178932 ·Status: COMPLETED ·Phase: NA
-
Epigenetic Regulation of BDNF in Schizophrenia
NCT01021449 ·Status: COMPLETED
-
A Study on Etiological Factors of Schizophrenia
NCT00155636 ·Status: TERMINATED
-
Neuroendocrine and Metabolite Substrates in Schizophrenia
NCT02423096 ·Status: UNKNOWN
-
Therapeutic Drug Monitoring for Individualized Clozapine Therapy
NCT03523741 ·Status: UNKNOWN
-
Serum Clozapine and Cognition
NCT00951418 ·Status: COMPLETED
-
Evaluating Pharmacogenomics-Based Pharmacotherapy in Real-World Settings for Schizophrenia
NCT06700967 ·Status: NOT_YET_RECRUITING
-
Effect of Memantine on ERP in Early Schizophrenia and Healthy Subjects
NCT02233556 ·Status: UNKNOWN ·Phase: NA
-
NMDA-enhancing Treatment for Cognitive Dysfunction of Schizophrenia
NCT06021197 ·Status: RECRUITING ·Phase: PHASE2
-
The Establishment of the Early Intervention Program for Patients With Schizophrenia
NCT00172770 ·Status: UNKNOWN
-
A Long-Term Study of MP-214 in Patients With Receiving Multiple Drugs Schizophrenia
NCT01626885 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Sex Differences in NMDA-enhancing Treatment of Schizophrenia
NCT07122895 ·Status: RECRUITING ·Phase: PHASE2
-
Genetics of Schizophrenia
NCT00619437 ·Status: UNKNOWN
-
Quetiapine Related Neurochemical Changes as Measured by Magnetic Resonance Spectroscopy in Schizophrenia
NCT00797927 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy of Chronic Disease Self-management Program in People With Schizophrenia
NCT04503954 ·Status: COMPLETED ·Phase: NA